Strategic report Corporate governance Financial statements Financial statements Notes to the Company financial statements continued For the year ended 31 December 2016 58.
Profit for the year The details of the LTIP scheme are provided in note 38.
As at 31 December 2016, the total number of awards granted to employees of the As permitted by section 408 of the Companies Act 2006, the statement of comprehensive income of the Company is not presented as Company under the LTIPs during the life of the plans was 1,649,615 shares 2015: 1,649,615 and the total amount of the compensation part of these accounts.
The net income in the Company for the year is $77 million 2015: $133 million.
expenses charged to profit and loss is $2 million 2015: $2 million.
Included in the net income for the year is an amount of $125 million 2015: $202 million representing dividends received, $32 million of acquisition cost in relation to West-Ward Columbus acquisition 2015:$12 million, and $5 million 2015: $3 million representing the 59.
Management incentive plans current year charge of LTIPs and EIPs whereby the remaining charge $17 million 2015: $12 million of the Groups stock options, LTIPs, MIPs and EIPs charge is recharged to subsidiary companies.
The details of the MIP scheme are provided in note 38.
As at 31 December 2016, the total number of awards granted to employees of the Company under the MIP during the life of the plans was 25,716 shares 2015: 18,383 shares and the total amount of the compensation expenses charged to profit and loss is $nil 2015: $nil.
Related parties Amounts repayable to and from subsidiaries are disclosed in Notes 48 and 52.
Executive incentive plans Other transactions with related parties include management charges for services provided to the subsidiary companies, equity settled The 2014 Executive Incentive Plan EIP was approved by shareholders at the 2014 Annual General Meeting.
The details of the EIP employee share scheme costs relating to the subsidiary companies and transactions with key management personnel.
Compensation paid scheme are provided in note 38.
As at 31 December 2016, the total number of awards granted to employees of the Company under the to key management personnel is disclosed in Note 40.
Details of Directors remuneration are disclosed in the Remuneration Committee EIP during the life of the plans was 364,274 shares 2015:153,209 and the total amount of the compensation expenses charged to profit Report on pages 104 to 135. and loss is $ 3 million 2015: $1 million.
More details on the general information of the ultimate parent of the Group are disclosed in Note 2.
Contingent liabilities Issued and fully paid - included in shareholders equity: A contingent liability existed at the balance sheet date in respect of Standby Letter of Credit totalling to $9 million 2015: $9 million.
Share premium Share premium $m Balance at 1 January 2016 282 Premium arising on exercise of stock options Balance at 31 December 2016 282 Annual Report 2016 209 200 Hikma Pharmaceuticals plc Annual Report 2016 201
